Clinical trials: Auto Immune Disease
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home
The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver…
- Trial name
- GRECO (NCT02918071)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Crohn's Disease
Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with moderately active Crohn's disease after injection for 28days.
- Trial name
- NCT02000362
- Testing
- Stem cells
- Where
- 7 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Food Allergy, Anaphylaxis
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
This is an open-label, three-part study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as a single dose of L-dipivefrin (IN-001) sublingual spray or drop in healthy adults.
- Conditions
- Food Allergy, Anaphylaxis, Food Hypersensitivity, Food Allergy Peanut
- Trial name
- NCT07210320
- Testing
- Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Insignis Therapeutics, Inc.
Asthma
A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
Mepolizumab (SB-240563) is a humanized monoclonal antibody (Immunoglobulin G1, kappa, mAb) that blocks human interleukin-5 (hIL-5) from binding to the interleukin (IL)-5 receptor complex expressed on the eosinophil cell surface…
- Trial name
- NCT03014674
- Testing
- Lyophilized mepolizumab, Liquid mepolizumab, Prefilled autoinjector
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Relapsing Remitting
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is…
- Trial name
- NCT02247310
- Testing
- Interferon beta-1b (Betaferon®, BAY 86-5046), BETACONNECT
- Where
- 11 sites in Austria, Belgium and 9 more
- Volunteers
- 498 people
- Sponsor
- Bayer
Sjögrens Disease, Systemic Lupus Erythematosus
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL…
- Conditions
- Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- NCT06293365
- Testing
- VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
- Where
- 37 sites in United States, Argentina and 6 more
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Redirected Auto T Cells for Advanced Myeloma
The purpose of this study is to 1) evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A2+ subjects and 2) measure the incidence of GVHD…
- Trial name
- NCT01352286
- Testing
- Autologous Genetically modified T cells
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Auto Immune Disease
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to…
- Trial name
- NCT07132112
- Testing
- GT719 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Grit Biotechnology
Crohn's Disease, Inflammatory Bowel Disease
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.
- Trial name
- NCT01009281
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus (SLE)
Descartes-08 for Patients With Systemic Lupus Erythematosus
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
- Trial name
- SLE-001 (NCT06038474)
- Testing
- Descartes-08
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cartesian Therapeutics
Oral Mucositis, Lymphoma
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell…
- Conditions
- Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer
- Trial name
- Capella (NCT05493800)
- Testing
- MIT-001, normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- MitoImmune Therapeutics
Systemic Lupus Erythematosus
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to characterize the pharmacokinetic profile and safety profile of 200 mg single dose of belimumab…
- Trial name
- NCT04136145
- Testing
- Belimumab for IV, Belimumab for SC
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Autoimmune Hepatitis
Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis.
This will be a prospective, observational, cross-sectional study designed to assess how a quantitative Magnetic Resonance Imaging (MRI) scan will aid in a physicians' clinical decision making process in patients with suspected or…
- Trial name
- NCT03979053
- Testing
- Multiparametric MRI Scan
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Perspectum
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Anaphylaxis
Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device
Through several questionaries the investigators will measure the satisfaction of patients diagnosed with anaphylaxis in the use of a medical device for the adrenaline autoinjector, a smart case for an epinephrine autoinjector…
- Trial name
- NCT02854969
- Testing
- Device: Anapphylaxis
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Adan Medical Innovation, SL
Rheumatoid Arthritis
Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the serum concentration of tabalumab after the administration using either prefilled syringe or auto-injector after the initial loading dose and after 12 weeks of treatment.
- Trial name
- NCT01676701
- Testing
- Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
- Where
- 37 sites in United States, Argentina and 4 more
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Chronic Plaque Psoriasis
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for…
- Trial name
- NCT02852967
- Testing
- Belumosudil
- Where
- 14 sites in United States
- Volunteers
- 110 people
- Sponsor
- Kadmon Corporation, LLC
Healthy Subjects
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects
This study is a first-in-human phase I randomised, double-blind, placebo-controlled, evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single (IV and SC) and Multiple (IV only)…
- Trial name
- NCT03980080
- Testing
- OSE-127
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- OSE Immunotherapeutics